Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR6.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR4.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR9.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR8.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR5.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR2.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR1.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR7.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR3.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR10.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR14.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR16.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR17.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR13.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR15.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR11.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR18.htm
XML - IDEA: XBRL DOCUMENT - POWER 3 MEDICAL PRODUCTS INCR12.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 10-Q/A
 

 
 (Mark One)
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
 
For the quarterly period ended June 30, 2011

OR
 
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
  For the transition period from                     to                    .
 
Commission file number: 000-24921
 
POWER3 MEDICAL PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
 
New York
65-0565144
(State or other jurisdiction of incorporation or organization)  
(I.R.S. Employer Identification No.)

 
26022 Budde Road
The Woodlands, Texas 77380
(Address of Principal Executive Offices)
 
(281) 298-7944
(Issuer's Telephone Number, including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes x    No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x    No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer o
Accelerated filer o
Non-accelerated filer o  
(Do not check if a smaller reporting company)
Smaller reporting company x
 
 
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)    Yes  o No  x

APPLICABLE ONLY TO ISSUERS INVOLVED IN
BANKRUPTCY PROCEEDINGS DURING THE
PRECEDING FIVE YEARS:
 
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.   Yes  o   No  o
 
 
APPLICABLE ONLY TO CORPORATE ISSUERS:
 
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:  There were 554,910,730 shares of the issuer’s common stock, $0.001 par value per share, issued and outstanding on August 16, 2011.
 
 
 
 

 
 

EXPLANATORY NOTE - AMENDMENT
 
The sole purpose of this Amendment No. 1 to the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011 of  Power3 Medical Products, Inc.  (the “Company”) filed with the Securities and Exchange Commission on August 23, 2011 (the “Form 10-Q”) is to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T.
 
No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.
 
 
 
 

 

ITEM 6. EXHIBITS

The following exhibits are filed as part of this report:
 
31.1
Rule 13a-14(a) Certification of Chief Executive Officer*
31.2
Rule 13a-14(a) Certification of Chief Financial Officer*
32.1
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of Chief Executive Officer*
101.INS
XBRL Instance Document **
101.SCH
XBRL Taxonomy Extension Schema Document **
101.CAL
XBRL Taxonomy Extension Calculation Linkbase **
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document **
101.LAB
XBRL Taxonomy Extension Label Linkbase Document **
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document **
 
* These exhibits were previously included or incorporated by reference in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011, filed with the Securities and Exchange Commission on August 10, 2011.
 
** Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, and otherwise are not subject to liability under those sections.
 
 
 

 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
POWER3 MEDICAL PRODUCTS, INC.
       
Date:  September 14, 2011
By:
/s/ Helen R. Park
 
   
Helen R. Park
 
   
Chief Executive Officer